11/19
08:20 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/19
04:37 am
fate
Rating for FATE
Medium
Report
Rating for FATE
11/19
04:37 am
fate
Rating for FATE
Medium
Report
Rating for FATE
11/13
08:06 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/13
05:12 am
fate
Rating for FATE
High
Report
Rating for FATE
11/13
05:12 am
fate
Rating for FATE
High
Report
Rating for FATE
11/13
12:45 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
11/13
12:45 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.